Edgewise Therapeutics Cash Flow Statement
NASDAQ: EWTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
39.06-0.17 (-0.43%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Edgewise Therapeutics free cash flow
In fiscal 2025, Edgewise Therapeutics generated -$143.8 million of operating cash flow and spent $256,000 on capital expenditures. That left free cash flow of -$144.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Edgewise Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -167.79M | -133.81M | -100.16M | -67.64M | -42.81M | -17.12M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 2.08M | 2.07M | 1.55M | 368.00K | 272.00K | 185.00K |
| Stock-Based Compensation | 34.75M | 24.71M | 17.56M | 10.92M | 4.40M | 354.00K |
| Change in Working Capital | -7.69M | 5.03M | -3.65M | -1.41M | 262.00K | 104.00K |
| Operating Cash Flow | -143.82M | -109.03M | -91.95M | -52.63M | -33.51M | -14.63M |
| Capital Expenditures | -256.00K | -1.31M | -5.75M | -5.55M | -668.00K | -203.00K |
| Investing Cash Flow | -32.79M | -184.66M | 102.89M | -70.58M | -242.23M | -24.38M |
| Financing Cash Flow | 196.09M | 249.25M | 53.17M | 129.64M | 186.38M | 120.28M |
| Net Change in Cash | 19.48M | -44.43M | 64.10M | 6.43M | -89.35M | 81.26M |
| Free Cash Flow | -144.07M | -110.34M | -97.69M | -58.18M | -34.17M | -14.84M |
This table shows 6 annual periods of Edgewise Therapeutics's cash flow statement, from FY 2025 back to FY 2020, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow EWTX's reporting calendar. What is a cash flow statement?